Patents by Inventor Ashwani K. Khanna

Ashwani K. Khanna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of TGF-? antagonists to limit nephrotoxicity of immunosuppressive agents
    Patent number: 7867496
    Abstract: The disclosure relates to methods of ameliorating nephrotoxic side effects of immunosuppressive agents whose immunosuppressive activity is mediated via upregulation of TGF-? such as, for example, cyclosporine (CsA). The disclosure provides treatment modalities for use in patients that require immunosuppression, e.g., patients at risk of transplant rejection or having an autoimmune disease. In the methods of the invention, a TGF-? antagonist, e.g., an anti-TGF-? antibody, is administered to a patient treated with an immunosuppressive agent. Such a TGF-? antagonist is administered in a therapeutically effective amount sufficient to alleviate the nephrotoxic effects of the immunosuppressive agent without substantially interfering with immunosuppressive activity of the agent.
    Type: Grant
    Filed: September 22, 2005
    Date of Patent: January 11, 2011
    Assignees: Genzyme Corporation, The MCW Research Foundation, Inc., National Institutes of Health
    Inventors: Ashwani K. Khanna, Steven Ledbetter
  • Use of Tgf-beta Antagonists to Limit Nephrotoxicity of Immunosuppressive Agents
    Publication number: 20090035304
    Abstract: The disclosure relates to methods of ameliorating nephrotoxic side effects of immunosuppressive agents whose immunosuppressive activity is mediated via upregulation of TGF-? such as, for example, cyclosporine (CsA). The disclosure provides treatment modalities for use in patients that require immunosuppression, e.g., patients at risk of transplant rejection or having an autoimmune disease. In the methods of the invention, a TGF-? antagonist, e.g., an anti-TGF-? antibody, is administered to a patient treated with an immunosuppressive agent. Such a TGF-? antagonist is administered in a therapeutically effective amount sufficient to alleviate the nephrotoxic effects of the immunosuppressive agent without substantially interfering with immunosuppressive activity of the agent.
    Type: Application
    Filed: September 22, 2005
    Publication date: February 5, 2009
    Inventors: Ashwani K. Khanna, Steven Ledbetter